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Abstract
Objective—To evaluate prognostic risk factors for survival in women with low grade serous 
epithelial ovarian cancer (LGSC).
Methods—A multicenter retrospective analysis of patients with LGSC was conducted. Potential 
epidemiologic risk factors evaluated included obesity, age, parity, race, smoking, oral 
contraceptive pill and/or hormonal replacement therapy use, and previous hysterectomy or surgery 
on fallopian tubes and/or ovaries. Additional factors included stage, extent of debulking, residual 
disease, and disease status.
Results—Eighty-one patients were identified, and pathological diagnosis was independently 
confirmed. Median age of diagnosis was 56 years (range: 21 to 86). Thirty-four percent were 
obese, and 80% had optimally debulked disease. Forty-six percent were alive, 14% with disease; 
while 25% were dead of disease; 2% died of intercurrent disease; and 27% had an unknown status. 
In a univariate analysis, optimal surgical debulking was associated with improved PFS (p=0.01), 
DSS (p=0.03), and OS (p<0.001 and BMI with worse OS (p=0.05). On multivariate analysis, 
obesity (HR=2.8; 95% CI=1.05-7.3; p=0.04) and optimal tumor debulking (HR=0.05; 95% 
CI=0.008-0.29; p=0.001) were a significant predictor of OS.
Conclusions—In a multivariate analysis, obesity and optimal tumor cytoreduction were 
significant predictors of OS. However, obesity was not associated with worse DSS, suggesting 
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that mortality of obese patients with LGSC may result from other co-morbidities. Interventions 
addressing obesity may improve survival for women diagnosed with LGSC and further study is 
warranted to address the role of obesity in LGSC.
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Introduction
Ovarian cancer comprises a heterogeneous group of tumors with a wide variation in clinical 
behaviors, histologies, and molecular features. Low grade serous ovarian carcinomas 
(LGSC) represent about 10% of all ovarian cancers (1). In 2004, Malpica et al. proposed a 
two-tier grading system for ovarian cancer that classified Grade 2 and 3 tumors as high 
grade and Grade 1 tumors as low grade (2). LGSC comprises one subtype of type 1 
epithelial ovarian cancers (EOCs) as proposed by Kurman and Shih (3). Patients diagnosed 
with LGSC are younger, (4, 5) live longer, (5, 6) and their disease is more likely to be 
confined to the ovary (5). Although LGSC may arise de novo, LGSC may arise from benign 
serous adenofibromas and serous tumors of low malignant potential (7). Due to the indolent 
nature of LGSC, optimal surgical debulking remains the frontline treatment because 
recurrent or persistent disease traditionally responds poorly to chemotherapeutics, (8) and 
patients may ultimately die from the burden of their recurrent disease (9).
Due to the prolonged disease course, potentially modifiable risk factors could alter the 
course of disease. To our knowledge, only one other study has investigated modifiable 
factors that may contribute to outcomes in women with LGSC. Schlumbrecht et al. found 
that smoking had a negative association with overall survival (OS) and progression free 
survival (PFS). Although not significant, patients who received hormonal consolidation 
(tamoxifen, letrozole, or leuprolide) after primary chemotherapy therapy had longer OS and 
PFS (10). When viewed as a single entity, non-modifiable risk factors for EOC include a 
family history of ovarian cancer, increasing age, early age of menarche and late age of 
menopause. Protective factors for development of EOC include increasing parity, a history 
of oral contraceptive use, oophorectomy, bilateral tubal ligation, and previous hysterectomy. 
Modifiable risk factors suspected to increase development of ovarian cancer include 
hormone-replacement therapy, high fat diet, obesity, smoking history, alcohol use, and 
inactivity (11). The relationship between body mass index (BMI), obesity, and ovarian 
cancer is uncertain, and there is minimal data about obesity and outcomes in women with 
LGSC.
Due to the rather indolent course of LGSC and lack of information regarding prognostic 
factors and conflicting results regarding obesity, we sought to evaluate prognostic 
modifiable and non-modifiable risk factors for women with this disease.
Materials and Methods
Each institution obtained Institutional Review Board approval. A database was created to 
identify all patients diagnosed with LGSC between January 1996 and December 2010. 
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When available, archival pathology slides were reviewed by gynecologic pathologists (SB, 
SW, and MD) to verify that the neoplasms were LGSC. Pathologic inclusion criteria were 
based on the two-tier grading system for serous ovarian carcinoma originally described by 
Malpica et al (2). Briefly, serous ovarian tumors with:
1. relatively uniform round to oval nuclei with mild to moderate atypia and evenly 
distributed chromatin,
2. ≤ 12 mitotic figures/10 high power fields, and 3. definitive stromal invasion >5mm, 
were considered LGSC. When pathology slides were not available, the original 
pathology report was reviewed and grade 1 disease was used as a surrogate for 
LGSC.
From medical charts, demographic data were abstracted. Patients who were lost to follow-up 
were excluded from analysis. Epidemiologic risk factors for EOC that were evaluated 
included obesity (BMI ≥ 30), BMI, age, parity, race, smoking, history of oral contraceptive 
pill/and or hormone replacement therapy use, previous hysterectomy, and previous surgery 
on fallopian tubes and/or ovaries. Other variables evaluated included stage of disease, 
residual disease after debulking, extent of debulking, and disease status. Information 
regarding residual disease and extent of debulking were obtained from the operative report. 
Optimal debulking was defined as residual disease less than 1 cm. BMI, defined as 
kilograms/meter squared (kg/m2), was used to classify patients as underweight (<18.5 
kg/m2), normal weight (≥18.5 to <25.0 kg/m2), overweight (≥25.0 to < 30.0 kg/m2), and 
obese (≥30.0 kg/m2). Cox proportional hazards modeling adjusted for age at diagnosis, 
status of tumor debulking, BMI, and history of use of hormone replacement therapy because 
these factors were thought to be relevant clinically.
Statistical analysis
Both univariate and multivariate Cox proportional hazards regression models were used to 
predict OS, disease specific survival (DSS) and PFS. Multivariate Cox proportional hazards 
modeling was conducted using the backward selection technique with an α = 0.50 (12) using 
the following candidate predictors: age at diagnosis, tumor debulking, obesity, BMI and a 
history of hormone replacement therapy use. OS was calculated from time of diagnosis to 
death due to any cause. For those still alive, it was censored at the last follow-up visit. DSS 
was calculated from time of diagnosis to death due to disease and was censored for deaths 
due to other causes or at last follow-up visit for those still alive. PFS was calculated from 
diagnosis until first recurrence or death, whichever occurred first, and was censored for 
those still alive without recurrence at last follow-up visit. A p-value < 0.05 was considered 
statistically significant. All statistical analyses were conducted using SAS version 9.2 (SAS 
Institute, Cary, NC).
Results
Eighty-one eligible patients were identified. Median age of diagnosis was 56 years (range: 
21 to 86). Thirty-four percent were obese (Table 1), and 90% had optimally debulked 
disease. At the study conclusion, 46% were alive, 14% with disease; while 25% were dead 
of disease; 2% died of intercurrent disease; and 27% had an unknown status (Table 1). The 
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diagnosis of LGSC was confirmed by review of glass slides for 58 (71.6%) and by review of 
original pathology reports for the remaining patients (23; 28.3%).
In a univariate analysis, BMI was associated with OS. Increasing BMI was associated with a 
1.4-fold increased risk of death (p=0.05) (Table 2). More specifically, a 5-unit increase in 
BMI was associated with a 1.4 fold increase risk in death, while a 10-unit increase was 
associated with a 2.1 fold increase risk of death. For instance a person with BMI of 35 or 40 
is 2.1 times more at risk of death than a person with a BMI of 25 or 30, respectively. 
Obesity, defined as a BMI ≥30.0 kg/m2, demonstrated a marginal association with worse OS 
(hazard ratio (HR)=2.08; confidence interval (CI) 0.93-4.66; p=0.07) in the univariate 
analysis. Using a multivariate Cox proportional hazards modeling to predict overall survival 
using age of diagnosis, status of tumor debulking, BMI, and history of use of hormone 
replacement therapy, obesity was associated with OS. The obese condition was associated 
with a 2.8 fold increase risk of death (p=0.04) (Table 3).
Surgical debulking and extent of residual disease were also associated with clinical outcome 
(Table 2 and 3). In a univariate Cox proportional hazards model, lower extent of residual 
disease (p=0.02) was associated with improved PFS, while optimal surgical debulking was 
associated with improved PFS (p=0.01), DFS (p=0.03), and OS (p<0.001) (Table 2). The 
majority of patients (94.3%) received adjuvant chemotherapy after initial cytoreduction. 
Primary regimens included carboplatin/paclitaxel (80%), carboplatin (1.43%), carboplatin/
topotecan (1.43%), carboplatin/paclitaxel/doxorubicin (1.43%), carboplatin/docetaxel 
(2.86%), cisplatin/paclitaxel (2.86%), platinum agent/cyclophosphamide (2.86%), and 
xyotax (1.43%). Since a high proportion of patients received chemotherapy, this variable 
was not tested in the predictive survival models. Hormonal therapy was also unable to be 
included in the predictive survival models because only four patients received tamoxifen 
after initial cytoreduction. Hormonal therapy was also unable to be included in the 
predictive survival models because only four patients received tamoxifen after initial 
cytoreduction. Debulking status was included in the multivariate model, however, due to the 
limited number of patients who were suboptimally cytoreduced (n=7), we could not reliably 
explore associations between tumor reduction and survival (Table 3).
Prediction of DSS and PFS using the backward selection technique did not identify two or 
more variable models; therefore, multivariate models could not be constructed for DSS or 
PFS. There was a trend toward worse median survival for obese women with LGSC 
compared to non-obese women (6.5 versus 9.5 years; p= 0.07) (Figure 1). There were no 
significant differences in DSS (8.4 versus 12.2 years; p=0.5) and PFS (1.5 versus 2.6 years; 
p=0.2) in obese and non-obese women with LGSC (Figure 2). There was no significant 
difference in optimal cytoreduction rates in obese and non-obese patients (88% in obese 
versus 93% in non-obese, p=0.7).
Discussion
BMI and obesity were predictors of survival for women with LGSC. We evaluated body 
habitus based on BMI and obesity in order to capture the effect of different weight 
classification on survival. In our univariate models, BMI and obesity were associated with a 
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significant 1.4-fold and a marginal 2.1-fold increased risk of death, respectively, but neither 
was associated with worse DSS. In our multivariate analysis, obesity was significantly 
associated with a 2.8-fold increased risk of death. In the multivariate model, the association 
between BMI and OS was lost. This is due to the high correlation between BMI and obesity. 
At the time of the analysis, 25% of the study population died. Longer follow-up is needed to 
determine the magnitude of obesity’s effect on survival in the patient population with a less 
aggressive tumor biology. Previously, Schlumbrecht et al. reported that patients with a BMI 
≥ 35 kg/m2 were identified as having a greater likelihood of dying (HR, 2.53; 95% CI, 
1.19-5.38; p = 0.02) (10). While one of the cutoffs for the study by Schlumbrecht et al. was 
BMI ≥ 35 and ours used BMI ≥ 30, the hazards ratios were comparable (2.53 versus 2.8). 
Furthermore, BMI assessed as a continuous variable was also associated with worse survival 
outcomes (HR=1.02, 95% CI, 1.00-1.1, p=0.05).
In contrast to our study, Schlumbrecht found that, residual disease after surgery was not 
statistically significant (p=0.29) for overall survival in a Cox univariate analysis. Tumor 
debulking has long been associated with improved outcomes in women with EOC (13). We 
were unable to explore associations between debulking status and survival due to the limited 
number of patients who were suboptimally cytoreduced. But, it is also important to note that 
optimal debulking rates did not differ in obese and non-obese women with LGSC. The 
majority of our patients received chemotherapy, so we were unable to test chemotherapy as 
a variable in our survival models due to the small number of patients who did not receive it. 
The effect of chemotherapy on LGSC warrants further study. Gershenson et al. reported 
relative insensitivity of LGSC to chemotherapy due to an observed low rate of patients who 
were clinically disease-free after adjuvant platinum-based chemotherapy (52%) (4). In a 
follow-up study, overall response rate to chemotherapy in 108 patients was only 3.8% in 
patients with recurrent LGSC (8). While chemotherapy does seem to have a less efficacious 
role in LGSC than in high grade disease, the majority of patients continue to receive 
frontline therapy, and chemotherapy does play an important role in the treatment of women 
with LGSC (14).
The relationship between BMI, obesity, and ovarian cancer is uncertain. Multiple studies 
have suggested that obesity does not negatively impact surgical outcomes, 
clinicopathological factors, (15) prognosis, (16, 17) or survival (15, 18) in all patients with 
EOC, when controlling for optimal debulking status (18) and whether the patient received 
optimal doses of chemotherapy or hormonal therapy (16). Other studies suggest that after 
adjustment for confounders including stage, grade, age, histology, residual disease, there is a 
trend toward shorter PFS in patients with a normal BMI, but OS is not significantly related 
to BMI (19). Conversely, results from other retrospective studies suggest that obesity was 
independently associated with both shorter time to recurrence and OS (20). BMI prior to and 
after diagnosis, as well as weight gain during adulthood, has also been associated with an 
increase in ovarian cancer mortality (21). Meta-analyses have attempted to better elucidate 
these conflicting results and suggest possible relationships between obesity in early 
adulthood and higher mortality among patients with EOC, (22) and slightly worse survival 
than non-obese women (23). Due to the variation between all of the studies, no definitive 
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conclusions may be drawn, however. These studies take into account all patients with EOC, 
and so far no attempts have been made to understand the impact of obesity of LGSC.
Given the obesity epidemic, it would be helpful to improve our understanding of its effect 
on ovarian cancer biology. The role of obesity in LGSC may be multi-factorial. Given the 
lack of association between obesity and DSS and PFS, mortality of obese patients with 
LGSC may result from other co-morbidities secondary to obesity. Patients diagnosed with 
LGSC represent a unique population as compared to those diagnosed with other types of 
EOC. LGSC patients tend to live longer and have more indolent disease. The natural history 
of this disease may render lifestyle modifications worthwhile, particularly if the tumor 
microenvironment is adversely affected by excess adipose tissue. The GOG is currently 
evaluating the impact of diet and exercise in survival and recurrence rates in women with 
newly diagnosed stage II-IV ovarian cancer after successful first-line therapy (GOG225). 
Data from this study may help determine if lifestyle modifications targeting obesity will 
improve survival in women with LGSC.
According to the World Health Organization (WHO), overweight and obesity are the fifth 
leading risk for global deaths, and at least 2.8 million adults die each year as a result. Over 
1.4 billion adults (age 20 and older) were overweight according to 2008 WHO estimates 
(24). Obesity comprises a major risk factor for complications including Type 2 diabetes, 
hypertension, hyperlipidemia, coronary artery disease and stroke. In our study, 28% of 
patients were diagnosed with hypertension which may contribute to higher incidence of 
coronary artery disease and/or stroke. However, only 6% of our study participants had 
diabetes. Our study did not take into account those patients with impaired fasting glucose or 
undiagnosed diabetes, and it is possible that we underestimated the percentage of patients 
with diabetes and LGSC. It is very likely that the association between obesity and worse 
survival we observed is secondary to obesity-related co-morbid conditions. In a prospective 
trial of more than 900,000 adults, BMI was associated with significantly higher rates of 
death in men and women due to a variety of cancers including esophagus, colon and rectum, 
liver, gallbladder, pancreas, and kidney. Furthermore, women with a higher BMI had a trend 
of increased risk of death due to cancers of the breast, uterus, cervix, and ovary (25).
In addition to obesity related illnesses, the increase risk of death in obese patients with 
LGSC may also be due to direct effects of obesity on carcinogenesis. Tumors in an obese 
environment may behave differently. Increased adipose tissue influences the bioavailability 
of sex steroids through multiple pathways. Obesity increases insulin resistance, 
bioavailability of sex hormones, and chronic inflammation that may promote the growth, 
rate or metastases of certain tumors (26). Leptin, found at higher concentrations in obese 
patients, induces expression of vascular endothelial growth factor, and may promote 
angiogenesis (27). The role of obesity on ovarian cancer in the literature provides conflicting 
evidence. It is possible that certain histopathologic types of ovarian cancer are more 
influenced by the obese environment. Furthermore, the association between obesity and risk 
of developing EOC may vary depending on tumor grade and the specific type of ovarian 
cancer. Increased height and obesity may be associated with an increased risk of 
endometroid types of EOC (28, 29). Elevated BMI has been associated with an increased 
risk for borderline serous (OR 1.24), invasive endometroid cancers (OR 1.17), and invasive 
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mucinous cancers (OR 1.19). There was no association with BMI and invasive serous 
cancers (OR 0.98) except for in premenopausal women (OR 1.11), but there was an 
increased risk for LGSC (OR 1.13) associated with higher BMI (30).
This study is limited by a small sample size. Also, we did not analyze outcomes related to 
treatment with chemotherapy or hormonal therapy due to the small number of patients who 
received and did not receive this type of therapy, respectively. We also did not evaluate 
outcomes after additional surgery if recurrence did occur. We used BMI calculated at the 
time of diagnosis and did not take into account BMI during adolescence, if BMI changed 
post-operatively, or BMI at the conclusion of treatment. Recent studies suggest that 
adolescent exposure to obesity is associated with worse OS in women who develop EOC 
(22).
Pathology was reviewed for over 70% of patients included in this study to incorporate newer 
definitions of low grade disease. For the remaining patients, pathology was not reviewed 
often because the original slides were returned to the referring laboratories, but the diagnosis 
of Grade 1 disease was used as a surrogate for low grade disease. Additionally, 27% of our 
study population was unknown or lost to follow-up. Although the mean ages and BMIs 
between the lost to follow-up group was similar to the group with outcome data, this could 
potentially affect our results. Future prospective and/or studies that address BMI over the 
course of a patient’s lifetime could validate the trends observed in this series.
Despite these limitations, our findings indicate that obesity and tumor cytoreduction are 
associated with overall survival outcomes in women with LGSC. Obesity is a modifiable 
risk factor that was associated with worse survival in women with LGSC. In addition, 
obesity may be related to DSS and PFS, but we were unable to detect an association due to 
our limited sample size. Further study is warranted to address the role of obesity and weight 
loss interventions in women with LGSC.
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Overall survival stratified by obesity status. There was a trend toward worse median survival 
for obese women with LGSC compared to non-obese women (6.5 versus 9.5 years; p= 0.07).
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Disease-specific and progression-free survival stratified by obesity status. There were no 
significant differences in DSS (8.4 versus 12.2 years; p=0.5) and PFS (1.5 versus 2.6 years; 
p=0.2) in obese and non-obese women with LGSC.
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Table 1
Clinicodemographic variables for patients with LGSC.
Prognostic factor Subgroups N Percentage
BMI 17 to < 25 28 35
25 to < 30 18 22
30 to <35 19 23
35 to < 40 6 7
40 or more 3 4
Not reported 7 9
History of HRT use Yes 10 12
No 59 73
Not reported 12 15
Previous surgery on tubes/ovaries Yes 12 85
No 69 15
Previous hysterectomy Yes 20 25
No 61 75
History of OCP use Yes 7 9
No 65 80
Not reported 9 11
Smoking history Previous history or current 15 19
Non-smoker 66 81
Debulking Optimal 65 80
Sub-optimal 7 9
Not reported 9 11




Not reported 2 2
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Prognostic factor Subgroups N Percentage
Not reported 8 10
Medical history CHF 2 2
Previous MI 3 4
CAD 1 1
Previous stroke 2 2
Hypertension 23 28
Diabetes mellitus 5 6
Deep vein thrombosis 5 6
Family history of ovarian cancer Yes 28 35
No 53 65
Disease status No evidence of disease 26 32
Alive with disease 11 14
Dead of disease 20 25
Dead of intercurrent causes 2 2
Unknown 10 12
Lost to follow-up 12 15
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Table 3
Multivariate Cox proportional hazards modeling to predict overall survival for obesity and optimal tumor 
debulking.
Hazard Ratio 95% CI p-value
Obesity 2.8 1.05-7.3 0.04
Optimal tumor debulking 0.05 0.008-0.29 0.001
Int J Gynecol Cancer. Author manuscript; available in PMC 2015 August 21.
